VBI Vaccines Inc

Headquartered in Cambridge (Massachusetts), VBI Vaccines Inc (NASDAQ: VBIV) is a Biopharmaceutical Company, which develops vaccine candidates for fighting infectious diseases, such as cytomegalovirus, hepatitis B, and coronaviruses, and glioblastoma.

Investment Rationale – Speculative Buy at USD 2.71

• From a technical standpoint, 14-day RSI (36.74) is hovering around the oversold position, and therefore, a short-term surge can be anticipated.
• VBIV’s stock has yielded a return of nearly 70.44% in the last one year and has significantly outperformed the benchmark Nasdaq index.
• In the past two years, VBIV has invested heavily in research and development, particularly in the 3-antigen prophylactic HBV (hepatitis B virus) vaccine candidate, which holds significant growth potential.
• The Company’s prospects seem promising as it has been preparing for commercialization of HBV vaccine, seeking regulatory approval of VBI-2902 (monovalent Covid-19-specific vaccine), and entered a partnership with Syneos Health and National Research Council of Canada.

Risk Assessments

• The Covid-19 pandemic continued to impact research programs, clinical studies, regulatory review, and site inspections.
• The Company has a history of losses, and it requires additional equity or debt to fund operations in the future.

Recent News

12 April 2021: VBIV affirmed that the Phase 1b/2a study of Hepatitis B Immunotherapeutic Candidate demonstrated T cell responses in more than or equals to 50% of evaluable patients, while the VBI-2601 (therapeutic vaccine candidate) was well-tolerated in both low and high dose levels.

Financial Highlights for the year ended 31 December 2020 (as on 2 March 2021)

 (Source: Company Website)

• During FY20, losses from operations and net losses significantly declined against FY19 despite the decrease in revenue.
• In December 2020, the Company announced the partnership with Syneos Health for the commercialization of 3-antigen HBV vaccine.
• As of 31 December 2020, VBIV had stockholders’ equity of nearly USD$171.7 million and an accumulated deficit of around US$308.6 million.
• At the end of FY20, the Company had cash and cash equivalent of US$93.8 million and nearly US$114.7 million of net working capital.

One Year Share Price Chart    

 (Source: Refinitiv, Thomson Reuters)

Conclusion

Given the significant unmet medical need of GBM (Glioblastoma Management), therapeutic HBV space and Covid-19 vaccine space, the Company has great potential for future growth. Moreover, the Company has invested heavily in R&D, which may bring additional pipeline candidates and other vaccine opportunities. Furthermore, the progress of Hepatitis B immunotherapeutic candidate shown in recent Phase 1b/2a study is boosting the confidence of the Company. The stock made a 52-week High and Low of USD 6.93 and USD 1.02, respectively.

Based on the operational achievement and business capabilities, we have given a “Speculative Buy” stance on VBI Vaccines Inc at the closing price of USD 2.71 (as on 16 April 2021).

Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc (NASDAQ: RIGL) is a biotechnology entity that develops small molecule drugs for cancer, virus, and autoimmune-related diseases.

Investment Rationale – Speculative Buy at USD 3.58

• From a technical standpoint, 200-day EMA (USD 3.23) indicating an upward trend in the stock.
• On 11 March 2021, Rigel completed the patient enrolment in a Phase 2 trial to evaluate the safety of fostamatinib. The National Heart, Lung, and Blood Institute sponsored the study. In the United States, the Fostamatinib is getting marketed as TAVALISSE®.
• Over the past two years (FY18 to FY20), revenue and gross profit have surged at a CAGR of 56.22% and 56.10%, respectively.
• Encouraged by the positive response of phase 2 trial in Covid-19 hospitalised patients of fostamatinib, while the Company has already launched phase 3 trial as well.

Risk Assessments

• The Company prospects are dependent upon its first commercial product, TAVALISSE, and the evolving conditions of the Covid-19 can adversely impact its performance.
• Intense competition, unfavourable regulatory updates, and challenges related to the distribution facilities can also impact business performance.

Recent News

13 April 2021: RIGL unveiled positive results of Phase 2 trial of fostamatinib in hospitalized patients with COVID-19.

7 April 2021: RIGL announced the closing of its licence agreement with Eli Lilly and Company, whereby it will receive US$125 million as upfront cash payment for supporting Rigel's RIP1 inhibitor program.

Financial Highlights for the year ended 31 December 2020 (as 2 March 2021)

 (Source: Company Website)

• For Q4 FY20, RIGL reported a net loss of US$19.2 million from US$17.2 million in Q4 FY19.
• During FY20, net sales for TAVALISSE was US$61.7 million, representing 41% growth on FY19.
• As of 31 December 2020, Rigel had nearly US$57.3 million in short-term investments, cash, and cash equivalents.
• The Company also received US$16.5 million from the US DOD’s (Department of Defense) to support the Phase 3 trial of fostamatinib, to check its effectiveness in the hospitalized Covid-19 patients.

One Year Share Price Chart   

 (Source: Refinitiv, Thomson Reuters)

Valuation Methodology: EV/Sales Approach (NTM) (Illustrative)

Conclusion

Rigel’s phase 2 clinical trial established significant progress for the Covid-19 drug development in extreme cases, which boosted the investor sentiments. Moreover, the FY20 results demonstrated a considerable decline in net loss per share with improved revenue generation. Adjacently, the annual price increase of TAVALISSE shall support the Company’s growth in the future as well. However, there are uncertainties in the short-term as patient-doctor interactions and fewer patient visits during Covid-19 conditions can impact business performance. However, the Company has substantial financial resources to navigate through this challenging phase and manage its project funding requirement and create a significant value for shareholders. The stock made a 52-week High and Low of USD 5.50 and USD 1.45, respectively.

Based on the positive Phase 2 clinical trial (fostamatinib), improved financials, business capabilities and valuation conducted above, we have given a “Speculative Buy” stance on Rigel Pharmaceuticals Inc at the closing price of USD 3.58 (as on 16 April 2021), with a lower double-digit upside potential based on 4.80x EV/NTM Sales (approx.) on FY21E Sales (approx.).

*All forecasted figures and Peer/Industry Information have been taken from Refinitiv, Thomson Reuters.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine do not hold interests in any of the securities or other financial products covered on the Kalkine website.